| Literature DB >> 14644389 |
Takamasa Hasegawa1, Atsushi Kosaki, Tatsuji Kimura, Hiroaki Matsubara, Yasukiyo Mori, Mitsuhiko Okigaki, Hiroya Masaki, Nagaoki Toyoda, Megumi Inoue-Shibata, Yutaka Kimura, Mitsushige Nishikawa, Toshiji Iwasaka.
Abstract
EN-RAGE is a ligand for the receptor for advanced glycation end products (RAGE) and may be involved in the development of diabetic macro- and micro-angiopathy. This study is designed to investigate the regulation of EN-RAGE gene expression in human macrophages. The amounts of EN-RAGE mRNA were measured in cultured human THP-1 macrophages after treatment with various stimuli known to modulate atherosclerosis. First, interleukin-6 (IL-6), a proinflammatory cytokine, increased the level of EN-RAGE mRNA by approximately 2-fold in a time- and a dose-dependent fashion. EN-RAGE protein was detected in the cultured medium and increased significantly by the addition of IL-6. The induction was abolished by pretreatment with the JAK kinase inhibitor and cycloheximide, but not with the MEK kinase inhibitor. Second, pioglitazone (PIO), a thiazolidinedione, decreased the level of EN-RAGE mRNA by approximately 25% of the basal in a time- and a dose-dependent fashion. Pioglitazone also inhibited the induction of EN-RAGE mRNA by IL-6. These results indicate the production of EN-RAGE is induced by IL-6 through de novo protein synthesis via the JAK-STAT kinase pathway and inhibited by the activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) in human macrophages. Copyright 2003 Elsevier Ireland Ltd.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14644389 DOI: 10.1016/j.atherosclerosis.2003.08.021
Source DB: PubMed Journal: Atherosclerosis ISSN: 0021-9150 Impact factor: 5.162